Asthma biomarkers in the age of biologics

Allergy, Asthma & Clinical Immunology

Harold Kim, Anne K. Ellis, David Fischer, Mary Noseworthy, Ron Olivenstein, Kenneth R. Chapman and Jason Lee

Allergy, Asthma & Clinical Immunology 2017, 13:48 | Published on: 17 November 2017

Abstract

The heterogeneous nature of asthma has been understood for decades, but the precise categorization of asthma has taken on new clinical importance in the era of specific biologic therapy. The simple categories of allergic and non-allergic asthma have given way to more precise phenotypes that hint at underlying biologic mechanisms of variable airflow limitation and airways inflammation. Understanding these mechanisms is of particular importance for the approximately 10% of patients with severe asthma. Biomarkers that aid in phenotyping allow physicians to “personalize” treatment with targeted biologic agents. Unfortunately, testing for these biomarkers is not routine in patients whose asthma is refractory to standard therapy. Scientific advances in the recognition of sensitive and specific biomarkers are steadily outpacing the clinical availability of reliable and non-invasive assessment methods designed for the prompt and specific diagnosis, classification, treatment, and monitoring of severe asthma patients. This article provides a practical overview of current biomarkers and testing methods for prompt, effective management of patients with severe asthma that is refractory to standard therapy.

Full Text | PDF

(You must be logged in to add and reply comments)

Interasma on Twitter

Interasma RT @worldallergy: WISC 2018 - Florence Dec. 6-9 Registration online will be closed on November 20th. After this date, registration will on…
17hreplyretweetfavorite
Interasma RT @worldallergy: Top 10 Scientific Articles in the field of psychosocial aspects of allergy published in 2017 (or 2016 as noted). https://…
17hreplyretweetfavorite
Interasma RT @Aller_MD: “#Asthma biologic prices ‘far out of alignment’ with benefit, says ICER” https://t.co/rIKq8LypH9 https://t.co/t8vGuROsUw
17hreplyretweetfavorite
Interasma RT @Aller_MD: “Risk Factors ID'd for Persistent Atopic Dermatitis in Kids Could help clinicians personalize disease prediction” https://t.c…
17hreplyretweetfavorite
Interasma RT @RhinologyO: “The otolaryngologists’ non-surgical training needs to extend beyond the limits of ENT” http…
18hreplyretweetfavorite

Editor: Juan C. Ivancevich, MD

Copyright © Interasma 2003-2017  •  Terms of Use  •  Privacy Policy  •  Contact Us  •  Sitemap

Powered by FREI SA

InterAsma